Superworth

Exelixis price to sales ratio EXEL

Market value divided by revenue over the last twelve months, since 2012.

Today, Nov 2, 2026
7.1×
10-year median
5.5×
Against its 10-year history
67th
percentile: 0 is its lowest day, 100 its highest
10-year range
3.1× to 53.5×
Peer median
7.4×

Exelixis' price to sales ratio is 7.1× as of Nov 2, 2026.

That is above its ten-year median of 5.5×, higher than on 67% of days in the last ten years.

Over that time it ranged from 3.1× in Dec 2022 to 53.5× in Feb 2017.

The median for 10 biotech stocks of a similar size is 7.4×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far7.1×4.6×7.1×
20255.4×4.4×5.5×
20244.6×3.2×5.0×
20234.2×3.2×4.2×
20223.2×3.1×5.1×
20214.6×4.0×7.8×
20206.5×4.8×8.4×
20195.8×5.0×9.5×
20187.8×6.4×22.8×
201721.9×18.7×53.5×
201634.5×23.8×48.6×
201537.1×14.4×47.4×
201411.7×11.7×43.8×
201331.4×6.4×31.4×
20126.2×2.4×7.3×

Against its peers

Companies in Biotechnology nearest Exelixis' size, closest first, today.

Where Exelixis ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Exelixis

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.